PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för camostat mesylate. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

24 hits

Bibliografisk träff 2021-03-04

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.

Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, Søgaard OS, Hasselstrøm JB, Winkler M, Hempel T, Raich L, Olsson S, Danov O, Jonigk D, Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Kjolby M, Braun A, Sheltzer JM, Pöhlmann S.

EBioMedicine · research-article; journal article · DOI 10.1016/j.ebiom.2021.103255

Bibliografisk träff 2021-02-27

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.

Weiss J, Bajraktari-Sylejmani G, Haefeli WE.

Chem Biol Interact · research-article; journal article · DOI 10.1016/j.cbi.2021.109428

Bibliografisk träff 2020-11-22

Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.

Breining P, Frølund AL, Højen JF, Gunst JD, Staerke NB, Saedder E, Cases-Thomas M, Little P, Nielsen LP, Søgaard OS, Kjolby M.

Basic Clin Pharmacol Toxicol · review; journal article · DOI 10.1111/bcpt.13533

Bibliografisk träff 2020-11-16

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation.

Hofmann-Winkler H, Moerer O, Alt-Epping S, Bräuer A, Büttner B, Müller M, Fricke T, Grundmann J, Harnisch LO, Heise D, Kernchen A, Pressler M, Stephani C, Tampe B, Kaul A, Gärtner S, Kramer S, Pöhlmann S, Winkler MS.

Crit Care Explor · brief-report; journal article · DOI 10.1097/cce.0000000000000284

Bibliografisk träff 2020-07-21

Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.

Ragia G, Manolopoulos VG.

Eur J Clin Pharmacol · review-article; review; journal article · DOI 10.1007/s00228-020-02963-4

Bibliografisk träff 2020-04-29

Camostat mesilate therapy for COVID-19.

Uno Y.

Intern Emerg Med · letter · DOI 10.1007/s11739-020-02345-9

Bibliografisk träff 2018-11-02

Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.

Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, Wakabayashi M, Sakasegawa N, Kodaka Y, Ueki N, Gudis K, Kawamoto C, Iwakiri K.

Digestion · journal article · DOI 10.1159/000492813

Bibliografisk träff 2016-06-16

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report.

Ota S, Hara Y, Kanoh S, Shinoda M, Kawano S, Fujikura Y, Kawana A, Shinkai M.

Respir Med Case Rep · journal article; case reports; case-report · DOI 10.1016/j.rmcr.2016.06.005

Bibliografisk träff 2016-01-20

Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.

Narita Y, Ueda M, Uchimura K, Kakizoe Y, Miyasato Y, Mizumoto T, Morinaga J, Hayata M, Nakagawa T, Adachi M, Miyoshi T, Sakai Y, Kadowaki D, Hirata S, Mukoyama M, Kitamura K.

J Pharmacol Sci · journal article · DOI 10.1016/j.jphs.2016.01.003

Bibliografisk träff 2015-03-03

The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.

Ueda M, Uchimura K, Narita Y, Miyasato Y, Mizumoto T, Morinaga J, Hayata M, Kakizoe Y, Adachi M, Miyoshi T, Shiraishi N, Kadowaki D, Sakai Y, Mukoyama M, Kitamura K.

Nephron · research support, non-u.s. gov't; journal article · DOI 10.1159/000375308

Bibliografisk träff 2014-10-01

[Camostat mesilate, a protease inhibitor, inhibits visceral sensitivity and spinal c-fos expression in rats with acute restraint stress].

Zhao J, Wang Z, Zou B, Song Y, Dong L.

Nan Fang Yi Ke Da Xue Xue Bao · journal article

Bibliografisk träff 2010-07-01

Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate.

Takahagi S, Shindo H, Watanabe M, Kameyoshi Y, Hide M.

Acta Derm Venereol · letter; case reports · DOI 10.2340/00015555-0869

Bibliografisk träff 2009-10-30

Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease.

Sai JK, Suyama M, Kubokawa Y, Matsumura Y, Inami K, Watanabe S.

J Gastroenterol · controlled clinical trial; journal article · DOI 10.1007/s00535-009-0148-1

Bibliografisk träff 2007-03-12

The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents.

Ishikura H, Nishimura S, Matsunami M, Tsujiuchi T, Ishiki T, Sekiguchi F, Naruse M, Nakatani T, Kamanaka Y, Kawabata A.

Life Sci · comparative study; journal article · DOI 10.1016/j.lfs.2007.02.044

Bibliografisk träff 2006-04-01

Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?

Ashizawa N, Hashimoto T, Miyake T, Shizuku T, Imaoka T, Kinoshita Y.

J Gastroenterol Hepatol · multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1440-1746.2005.04041.x

Bibliografisk träff 2005-01-01

Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).

Ohkoshi M, Sasaki Y.

In Vivo · comparative study; journal article

Bibliografisk träff 1997-10-01

Inhibitory effect of a serine protease inhibitor, FOY-305 on the invasion and metastasis of human pancreatic cancers.

Ohta T, Futagami F, Tajima H, Kitagawa H, Kayahara M, Nagakawa T, Miwa K, Yamamoto M, Iseki S, Nakanuma Y, Terada T.

Int J Oncol · journal article · DOI 10.3892/ijo.11.4.813

Bibliografisk träff 1997-05-01

Growth-suppressive activities of serine protease inhibitors, FOY-305, ONO-3403 and FO-349 toward human carcinoma cells.

Ohkoshi M, Denda T, Hiwasa T.

Oncol Rep · journal article · DOI 10.3892/or.4.3.521

Bibliografisk träff 1996-10-01

[Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer].

Ohta T, Futagami F, Arakawa H, Tsukioka Y, Kitagawa H, Kayahara M, Nagakawa T, Miyazaki I.

Gan To Kagaku Ryoho · review; journal article

Bibliografisk träff 1996-09-01

Enhancement of anti-proliferative activities of 5-FU, HCFU, SN-38, THP and ACNU by a serine protease inhibitor, FOY-305.

Hiwasa T, Tokita H, Hirose M, Ike Y, Ohkoshi M.

Int J Oncol · journal article · DOI 10.3892/ijo.9.3.517

Bibliografisk träff 1991-05-01

[Effects of FOY-305 on post-operative reflux esophagitis in rats (I). Effects of FOY-305 on reflux esophagitis after total gastrectomy in rats].

Kamiyasu K, Awata H, Inoshiri S, Doi A, Omawari N, Okegawa T, Kawasaki A, Shinomiya K, Tanaka M, Suzuki Y.

Nihon Yakurigaku Zasshi · comparative study; journal article · DOI 10.1254/fpj.97.5_241

Bibliografisk träff 1988-03-01

Suppressive effect of camostat mesilate (FOY 305) on acute experimental allergic encephalomyelitis (EAE).

Inuzuka T, Sato S, Baba H, Miyatake T.

Neurochem Res · research support, non-u.s. gov't; journal article · DOI 10.1007/bf00971537

Bibliografisk träff 1984-08-01

Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma.

Ohkoshi M, Oka T.

J Maxillofac Surg · journal article · DOI 10.1016/s0301-0503(84)80235-0

Bibliografisk träff 1981-12-01

Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate.

Ohkoshi M.

Gan · journal article